As Bitcoin faces market turbulence, MicroStrategy's executive chairman Michael Sayer reaffirms his unwavering commitment to the company's aggressive accumulation strategy, dismissing short-term volatility and highlighting long-term institutional adoption as key drivers.
Activist investor Nelson Peltz questions the rationale behind Josh D'Amaro's CEO appointment at Disney, implying Bob Iger's continued influence and highlighting D'Amaro's lack of core entertainment experience.
Pfizer Inc. reported stronger-than-expected Q4 and full-year 2025 results, returning $9.8 billion to shareholders. The pharmaceutical giant is navigating a pivotal transition, leveraging recent acquisitions and a promising obesity drug pipeline to offset upcoming patent expirations and drive growth beyond 2028.
As demand for AI compute power surges, infrastructure providers Applied Digital and CoreWeave are posting explosive growth. But behind the soaring revenues lie starkly different financial profiles and risks, forcing investors to look beyond the hype.
Amid growing geopolitical tensions, EU Financial Services Commissioner Maria Luís Albuquerque has called for Europe to assert control over foundational technologies, highlighting cybersecurity risks and economic vulnerabilities tied to foreign tech dependence.
Financial expert Suze Orman highlights a pervasive spending habit that is quietly consuming a quarter of the average retiree's Social Security income. As savings rates plummet and retail spending climbs, her advice to reclassify 'wants' as 'needs' strikes at the heart of a growing financial discipline crisis.
CNBC's Jim Cramer reaffirmed his confidence in AutoZone (AZO) during a recent 'Mad Money' segment, addressing investor concerns by highlighting the auto parts retailer's robust cash generation and operational strength.
CNBC's Jim Cramer has turned bullish on logistics giant C.H. Robinson, pointing to recent positive signals in the freight sector as a key catalyst for the stock's potential.
Food distribution giant Sysco saw shares jump nearly 11% after reporting better-than-expected quarterly results, prompting CNBC's Jim Cramer to highlight the stock as undervalued amid a broader market rally.
Jim Cramer's analysis of Southwest Airlines highlights the carrier's high-stakes operational overhaul amid pressure from activist investor Elliott Management, framing it as a pivotal moment for the low-cost pioneer.
CNBC's Jim Cramer voiced strong support for AstraZeneca when questioned by an investor considering a switch to AbbVie, highlighting the resilience of the pharmaceutical giant's oncology division.
A veteran Ohio mail carrier's social media post highlighting extreme winter working conditions led to his suspension, igniting a national conversation on employee safety and the legal tightrope of criticizing employers online.
Amid market turmoil following Kevin Warsh's nomination to lead the Federal Reserve, seasoned investor George Noble argues traders have misjudged the nominee as a hawk. He contends Warsh's dovish leanings will instead accelerate the monetary trends that have powered gold and silver to record highs.
A high-stakes White House meeting between banking and cryptocurrency industry leaders concluded without a breakthrough, failing to bridge a critical divide over stablecoin rewards that has stalled a major market structure bill for months.
Merck & Co. reported solid Q4 2025 results, driven by oncology and new launches, while detailing a robust pipeline it believes can deliver over $70 billion in commercial potential by the mid-2030s, aiming to ensure growth past Keytruda's patent expiration.
Even in the high-flying technology sector, compelling bargains exist. We examine three AI leaders whose current valuations may not fully reflect their long-term growth trajectories.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its injectable weight loss therapies, alongside forging two new research collaborations targeting hearing loss and autoimmune diseases, as its stock continues a meteoric rise.
After years of high-stakes drama, false starts, and a brief, turbulent reign, The Walt Disney Company has finally named its next leader. Theme parks chief Josh D'Amaro is set to take the helm, marking the end of Bob Iger's prolonged and interrupted exit and opening a new chapter for the entertainment giant.
The Walt Disney Company has detailed the lucrative compensation packages for incoming CEO Josh D’Amaro and President Dana Walden, with base salaries, substantial bonuses, and long-term stock awards positioning them among entertainment's highest-paid executives.
The FDA launches a new program to fast-track reviews for strategically important drug manufacturing facilities. In separate developments, AstraZeneca faces a setback for a lupus drug formulation, while Acadia Pharmaceuticals receives a negative signal from European regulators for its Rett syndrome therapy.
